Sector News

Bristol-Myers Squibb in $2.3B I-O biotech biobucks buyout deal

August 7, 2017
Life sciences

Bristol-Myers Squibb will pay $300 million upfront and up to $2 billion in biobucks for IFM Therapeutics and its new immuno-oncology approaches.

This comes just a year after the preclinical upstart raised a $27 million series A, with backing from Atlas Ventures, Abingworth and Novartis’ venture arm.

The Cambridge, Massachusetts-based company is currently working on developing a portfolio of first-in-class small molecules that aims to either boost inborn immune responses for treating cancer or dampen certain immune responses that drive many inflammatory diseases.

BMS wants the cancer assets now but may take on its other candidates down the line.

The $1.01 billion, which will be in addition to the $300 million upfront, comes in the form of milestones for each of the first products from the two programs, making it worth $2.3 billion in total.

This includes IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs, both focused on enhancing the innate immune response for treating cancer. BMS gains full rights to the programs.

IFM’s STING agonist program includes a lead asset that accelerates the company’s efforts against this target, while the NLRP3 agonist program includes a potential first-in-class pipeline candidate.

IFM is also in line for extra milestone payouts for other products coming out of these programs, although further details were not given.

And as part of the deal structure, a new spin-out will be made with shareholders of IFM, known as IFM Therapeutics LLC, holding on to its current personnel and facilities, as well as its remaining research programs.

This includes an NLRP3 antagonist program focused on curbing immune responses that lead to inflammatory diseases, as well as fibrosis.

BMS gets “certain rights” against the NLRP3 antagonist program, including a right of first refusal, it adds in a statement.

“Targeting innate immunity pathways represents a potentially differentiated approach in immuno-oncology designed to initiate and augment immune responses that may help the body’s natural defenses better recognize and attack tumors,” said Thomas Lynch Jr., M.D., executive vice president, CSO at Bristol-Myers Squibb, in a release.

“The addition of STING and NLRP3 agonist programs broadens our ability to investigate additional pathways across the immune system and complements our immuno-oncology portfolio. We look forward to advancing the development of these important programs initiated by Gary Glick, his leadership team and leading academic and industry experts across immunology and oncology.”

“A comprehensive body of preclinical data support the continued research of IFM’s NLRP3 and STING agonists with a goal of uncovering their potential benefit to patients, particularly those not served by currently available cancer immunotherapeutics,” added Gary Glick, Ph.D., CEO and co-founder of IFM Therapeutics, as well as a founder of Lycera, in the release.

This comes as BMS is looking to boost its own early-stage I-O pipeline, and as its major immuno-oncology med Opdivo (nivolumab) has suffered trial setbacks in the past year (although rivals Merck, AstraZeneca and Roche have also been beset in recent months).

It’s a fairy tale for IFM to be swept up in a blockbuster deal just a year after a series A and with such early-stage candidates.

Of course, BMS is no stranger to biotech buyouts; last year it spent $600 million to unlock autoimmune biotech upstart Padlock, and back in 2015 a $1.25 billion deal for another very young cancer biotech in Flexus, with a similar deal structure.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach